Literature DB >> 3391621

Is there a central nervous withdrawal syndrome associated with discontinuing long-term treatment with propranolol?

H al-Qassab1, L A Cleeves, P L Francis, M R al-Sereiti, L Findley, A Hedges, R Silman, P Turner.   

Abstract

Thirty healthy volunteers were treated with beta-adrenoceptor blocking doses of long-acting propranolol for at least 28 days before being randomized to continue propranolol treatment, receive identical placebo under double-blind conditions, or discontinue all treatment. No evidence of a central nervous withdrawal syndrome occurred during the next 28 days as assessed by changes in psychomotor tests, rating scales, visual analogue scales, tremor recordings and melatonin excretion. Three subjects in the placebo withdrawal group but none in the propranolol group complained of insomnia for up to 14 days of the withdrawal period.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391621     DOI: 10.1177/096032718800700303

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  2 in total

Review 1.  Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

Review 2.  Antihypertensive withdrawal for the prevention of cognitive decline.

Authors:  Susan Jongstra; Jennifer K Harrison; Terry J Quinn; Edo Richard
Journal:  Cochrane Database Syst Rev       Date:  2016-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.